T1	Participants 94 172	patients with type 2 diabetes inadequately controlled by metformin monotherapy
T2	Participants 471 551	patients with type 2 diabetes exhibiting inadequate glycemic control (A1C 7-11%)
T3	Participants 646 737	302 patients with type 2 diabetes (mean A1C 8.3%) on metformin monotherapy (mean 1.5 g/day)
T4	Participants 1767 1853	patients with type 2 diabetes who had inadequate glycemic control with metformin alone
T5	Participants 1963 1978	type 2 diabetes
